Jonathan C. Trent, MD, PhD, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.
Jonathan C. Trent, MD, PhD, a professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.
Angiosarcoma appears responsive to immune checkpoint inhibitors, says Trent. A study published in theJournal for Immunotherapy of Cancer, immune checkpoint inhibitors resulted in an approximate 70% complete or partial response rate in patients withangiosarcoma.
Trent notes that patients with cutaneous angiosarcoma appear to have the most benefit from immunotherapy. However, pleomorphic sarcoma and the differentiated liposarcoma still have a lot of progress to be made in terms of bringing immunotherapy into the day-to-day management of patients with soft tissue sarcoma.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More